Skip to main content

Table 2 Associations of methylation at AHRR, 6p21.33, and F2RL3 with lung cancer incidence in the validation set

From: Smoking-associated DNA methylation markers predict lung cancer incidence

CpG site

Methylation levela

Controls

Cases

OR (95% CI)

Model 1b

Model 2c

Model 3d

AHRR_cg05575921

≥85 (quartile 4)

59

6

Ref.

Ref.

Ref.

<85 (quartile 3)

73

1

<80 (quartile 2)

58

11

4.13 (1.48–11.52)

3.70 (1.12–12.22)

4.63 (1.27–16.80)

<68 (quartile 1)

45

47

23.93 (9.61–59.57)

17.17 (4.91–60.03)

15.86 (4.18–60.17)

Per SD less methylation

 

2.61 (2.02–3.37)

2.58 (1.69–3.94)

2.37 (1.46–3.85)

6p21.33_cg06126421

≥73 (quartile 4)

63

4

Ref.

Ref.

Ref.

<73 (quartile 3)

76

6

<66 (quartile 2)

50

12

3.90 (1.52–9.98)

3.00 (1.06–8.48)

4.08 (1.27–13.07)

<57 (quartile 1)

46

43

15.55 (6.89–35.10)

6.92 (2.63–18.18)

8.12 (2.69–24.48)

Per SD less methylation

 

2.92 (2.15–3.98)

2.11 (1.45–3.05)

2.11 (1.39–3.19)

F2RL3_cg03636183

≥81 (quartile 4)

113

5

Ref.

Ref.

Ref.

<81 (quartile 3)

39

5

<78 (quartile 2)

40

9

3.91 (1.45–10.55)

2.75 (0.91–8.37)

2.45 (0.72–8.31)

<73 (quartile 1)

43

46

19.25 (8.59–43.15)

10.84 (4.03–29.19)

10.55 (3.44–32.31)

Per SD less methylation

 

2.46 (1.90–3.19)

1.86 (1.33–2.60)

1.72 (1.17–2.51)

  1. Abbreviations: OR odds ratio, CI confidence interval, Ref. reference category, SD standard deviation
  2. aQuartiles of each site among controls in the training set
  3. bModel 1: adjusted for age and sex
  4. cModel 2: like model 1, additionally adjusted for smoking status and pack-years
  5. dModel 3: like model 2, additionally adjusted for educational level, BMI, physical activity, systolic blood pressure, total cholesterol, family history of cancer, prevalence of hypertension, cardiovascular disease, and diabetes